Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-guided cytomegalovirus prophylaxis in lung transplant recipients
2018-003300-39Phase 3Completed
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Cytomegalovirus disease incidence at 18 months. Started Oct 2018; status: completed.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2018-003300-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003300-39.